Spexis AG and Molecure Report Changes and Progress in Executive Committees and Clinical Trials

Spexis AG announces changes to its Executive Committee, with Hernan Levett leaving as Chief Financial Officer and Martin Jakobovic taking over. Molecure reports significant financial and operating momentum, including approval from the US FDA for clinical trials and plans for phase II trials. Spexis provides a business update and announces positive results for the first half of 2023, focusing on developing macrocycle therapeutics for rare diseases and oncology.